Skip to main content
CellSource Co.,Ltd. logo

CellSource Co.,Ltd. — Investor Relations & Filings

Ticker · 4880 ISIN · JP3423580004 T Human health and social work activities
Open in API
Filings indexed 48 across all filing types
Latest filing 2026-01-28 Audit Report / Informat…
Country JP Japan
Listing T 4880

About CellSource Co.,Ltd.

https://www.cellsource.co.jp/en/

CellSource Co., Ltd. is a biotechnology company specializing in regenerative medicine. It provides contract processing services to medical institutions for cells and tissues derived from adipose (fat) and blood. The company's core activities include the extraction and preparation of adipose-derived stem cells and the processing of blood-derived materials like Platelet-Rich Plasma (PRP). CellSource also offers support services to help medical facilities comply with relevant laws and regulations, aiming to advance the industrialization and accessibility of regenerative therapies.

Recent filings

Filing Released Lang Actions
確認書
Audit Report / Information Classification · 1% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under the Financial Instruments and Exchange Act, Article 24-4-2, Paragraph 1. This is a mandatory internal control certification filed alongside the Annual Securities Report (Yukashoken Hokokusho) in Japan. Since it is a regulatory filing confirming the accuracy of the annual report and does not contain the full financial statements or the report itself, it falls under the general regulatory filing category. FY 2025
2026-01-28 Japanese
有価証券報告書－第10期(2024/11/01－2025/10/31)
Annual Report Classification · 1% confidence The document is a Japanese '有価証券報告書' (Yuuka Shouken Houkokusho), which is the standard Japanese equivalent of an Annual Report (10-K). It contains comprehensive financial data, management discussion, and corporate information for the fiscal year ending October 31, 2025. It is not an announcement or a summary, but the full statutory filing submitted to the Kanto Local Finance Bureau. FY 2025
2026-01-28 Japanese
臨時報告書
Board/Management Information Classification · 1% confidence The document is titled '臨時報告書' (Extraordinary Report) and is submitted to the Kanto Local Finance Bureau. Section 1, '提出理由' (Reason for Submission), explicitly states that the company resolved on July 14, 2025, regarding a change in the Representative Director, citing Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act. Section 2 details the change in roles for two individuals, including the transition of '澤田 貴司' from '代表取締役社長CEO' (Representative Director, President & CEO) to '取締役会長' (Chairman of the Board) and the appointment of '山川 雅之' to the CEO role. This content directly corresponds to announcements of changes in senior management or board composition. Based on the definitions, this aligns perfectly with 'Board/Management Information' (MANG). The document is a formal regulatory filing announcing management changes.
2025-07-14 Japanese
訂正臨時報告書
Share Issue/Capital Change Classification · 1% confidence The document is a Japanese regulatory filing, indicated by the header information (e.g., 【提出書類】, 【提出先】). The key phrase in the header is "臨時報告書(2025年６月30日付け訂正報告書の添付インラインXBRL)" which translates to "Extraordinary Report (Inline XBRL attached to the Correction Report dated June 30, 2025)". The body explicitly states the purpose under "１【提出理由】" is to report the resolution by the Board of Directors regarding the issuance of stock options to employees, pursuant to Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act. Stock option issuance and related capital structure changes fall under the scope of Capital/Financing Update (CAP). Although it is a formal filing, the core subject matter is financing/capital structure change (stock options), making CAP the most specific fit over a general regulatory filing (RNS).
2025-06-30 Japanese
確認書
Regulatory Filings Classification · 1% confidence The document is a 'Confirmation Letter' (確認書) filed under the Financial Instruments and Exchange Act, which serves as an officer certification regarding the accuracy of a previously filed semi-annual report. According to the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations should be classified as Regulatory Filings (RNS), even if they reference a specific report type like an interim/semi-annual report. H1 2025
2025-06-12 Japanese
半期報告書－第10期(2024/11/01－2025/10/31)
Interim / Quarterly Report Classification · 1% confidence The document is a '半期報告書' (Semi-Annual Report) filed with the Kanto Local Finance Bureau under the Financial Instruments and Exchange Act. It contains comprehensive financial statements, including the balance sheet, income statement, and cash flow analysis for the interim period (November 1, 2024, to April 30, 2025). As it is a formal interim financial report containing substantive financial data, it is classified as an Interim/Quarterly Report (IR). H1 2025
2025-06-12 Japanese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.